What Ozempic Is Actually Cutting From The Basket

US households cut grocery spending by an average of 5.3% within six months of starting a GLP-1 medication, rising to more than 8% among higher-income households, according to a Cornell University study published in the Journal of Marketing Research and built on transaction data from roughly 150,000 households.

The same pattern is showing up well beyond the US. In the UK, households with a GLP-1 user spent a combined £780 million less on groceries than expected compared with non-user households, a £418 shortfall per household, according to Grocery Gazette's analysis of retail data. GLP-1 use in Great Britain has nearly tripled in two years, from 2.3% of households in 2024 to 6.3% in 2026, and PwC estimates the arrival of pill-form treatments could push UK uptake from roughly 3 million users to 7 million, about 13% of British adults. Novo Nordisk, maker of Ozempic and Wegovy, now sells GLP-1 drugs in 80 countries, with an estimated 14 million patients worldwide, meaning the basket-level effects showing up in Cornell's US data are an early read on a much larger global shift still working its way through. British data also shows how specific the substitution gets: chocolate spending fell 18 percentage points more in GLP-1 households than in others, while spending on mouthwash and chewing gum rose sharply, an unglamorous side effect retailers have nicknamed "Ozempic mouth."

The researchers matched retail and foodservice records from market-research firm Numerator against repeated surveys asking whether household members were taking GLP-1 drugs. They stopped short of isolating the medication as the sole cause, but spending patterns reversed once patients discontinued treatment, evidence the team cites in support of an appetite-driven explanation.

The packaged food industry had braced for a steeper hit. When GLP-1s were approved for obesity treatment in 2021, the fear was that users cutting up to 1,000 calories a day would buy proportionately less of everything. Instead, research firm Circana found GLP-1 households shifted their baskets rather than shrinking them: more fresh produce, protein and fibre, less in the way of sweets, salty snacks and sugary drinks, while continuing to outspend non-users overall.

Restaurant spending is expected to hold up better than grocery. Eating out, unlike a snack reached for at home, was rarely just about calories to begin with.

The categories disappearing fastest from GLP-1 baskets are not staples. They are items typically bought for reasons unrelated to hunger: the evening snack, the impulse sugary drink, the thing reached for out of boredom or stress rather than need. GLP-1 drugs blunt the physical signal that often got misread as appetite. What is left once that signal quiets is whatever the underlying feeling actually was.

That feeling has not disappeared from the household budget. Research from Acosta Group, published in April 2026, found GLP-1 users are redirecting spending rather than simply cutting it, with increases in personal care and wellness-related research.

The consumption shift is also not evenly distributed. Even after 2026 price cuts, Americans still pay two to four times what Europeans pay for the same drugs, roughly $350 to $699 a month in US cash prices versus €83 to €144 in Europe. States with the highest obesity rates also carry the steepest income burden for the medication, meaning the households with the most at stake in this shift are often the ones least able to afford joining it.

Alcohol is following a similar path, for two overlapping reasons rather than one. GLP-1 use itself appears to dampen the urge to drink: an EY-Parthenon survey found 44% of users cut back after starting the medication, and 82% of those kept the lower habit even after stopping. That is compounding a separate, generational shift already under way, most visibly among Gen Z, where the share who don't drink at all rose from 17% to 24% in a single year and daily drinking fell from 6% to 2%. Low- and no-alcohol brands, already built around a market that was choosing to drink less, find themselves positioned well ahead of a second wave of demand now arriving for pharmacological rather than generational reasons. Whichever reason applies in a given household, medication or simply changing taste, the same shelf of alternatives stands to benefit.